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Abstract 
 
Psoriasis (PS) and psoriatic arthritis (PsA) are subtypes of psoriatic disease (PD), a 
chronic inflammatory disorder with predominantly cutaneous manifestations. PsA is developed 
in approximately one third of patients with PS. These two phenotypes are immune-mediated 
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diseases with different heredity that might in part be explained by different genetic factors. We 
carried out an analysis of association between haplotypes of cytokine genes (TNFA, IL4 and 
IL10) and PD in Russians from East Siberian region of Russia. The haplotypes were not found to 
be associated with either PS or PsA. However, meta-analyses with published data suggested 
associations between PS and IL4 rs2243250 and TNFA rs1800629 polymorphisms, while PsA 
was found to be associated with IL4 rs2243250 only. The results provide further insight into 
understanding of genetic factors predisposing to PD.  
Abbreviations: PS, Psoriasis; PsA, Psoriatic arthritis, PD, Psoriatic disease; TNFα, 
Tumor necrosis factor-alpha; SNPs, Single nucleotide polymorphisms; DNA, Desoxyribonucleic 
acid; RFLP, Restriction fragment lengths polymorphism; PASI, soriasis Area and Severity 
Index.   
Keywords: Psoriatic disease; Psoriasis; Psoriatic arthritis; Haplotype; Cytokines 
 
1. Introduction 
 
Psoriasis (PS) is a common and stigmatizing chronic immune-mediated inflammatory 
skin disease characterized by the altered proliferation and differentiation of keratinocytes and 
affecting about 2% of the population worldwide with a high burden of disability and increased 
mortality (Boehncke and Schön, 2015; Bowcock and Krueger, 2005; Nestle et al., 2009). The 
main characteristics of psoriasis are excessive proliferation of keratinocytes and being easy to 
relapse; however, it was reported that the disease can affect many tissues in the muscles, joints, 
digestive tract and even eyes. Therefore, it is agreed that PS is one of the forms of psoriatic 
disease (PD) (Ritchlin, 2007; Meng et al., 2018). Psoriasis possesses a major social and 
economic burden on society as the existent therapies only relieve symptoms and cannot cure 
disease. Therefore, a better understanding of the immunopathogenesis of PS is essential for the 
development of improved therapies. 
Approximately one third of patients with PS develop psoriatic arthritis (PsA), a chronic 
inflammatory heterogeneous disease that can affect various distinct anatomical sites including 
peripheral and axial joints, entheses, skin and nails. Both PS and PsA are T-cell-mediated 
autoimmune diseases united under the term of psoriatic disease (Baliwag et al., 2015; Loft et al., 
2018; Sakkas and Bogdanos, 2017). Their pathogenesis is largely driven by the dysregulation of 
pro-inflammatory and anti-inflammatory cytokines production.  
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Psoriatic disease has a strong hereditary character and has a complex genetic background. 
Genome-wide association studies have identified polymorphisms within or near a number of 
genes encoding cytokines, cytokine receptors or elements of their signal transduction pathways, 
further implicating these cytokines in the pathogenesis. A considerable number of inflammatory 
cytokines have been shown to be elevated in lesioned psoriatic skin, and the serum 
concentrations of a subset of these also correlate with PD severity (Baliwag et al., 2015). 
According to the Phenopedia data (https://phgkb.cdc.gov/PHGKB/startPagePhenoPedia.action), 
the spectrum of genes involved in the pathogenesis of PS and PsA is diverse and distinguishes 
them from each other. Moreover, because of the complexity and heterogeneity of disease, 
pathogenetic links between PS and PsA are unclear (Ruiz et al., 2012). 
 The identification of cytokine gene polymorphisms and the study of their involvement in 
the pathogenesis of PD have been carried out in different populations with contradictory results, 
so as there is no completed picture of the association of the polymorphisms with PS and PsA. By 
far, no such studies have been carried out in Russian populations. The greatest interest for such 
studies is the polymorphisms of the TNFA gene, since TNF-α is the main mediator of 
inflammation in PD, which is confirmed not only by its participation in the cytokine regulation 
of cells interactions, but also by the success of anti-TNFα therapy (Mease, 2004). Despite the 
fact of undoubtful importance of cytokines produced by Th2 cells in the pathogenesis of PS, 
studies of the effect of polymorphism of their genes on predisposition to PS and PsA are limited. 
Until now, the role of the IL4 and IL10 genes in the development of PS and PsA is unclear. 
The aim of current study was to analyse associations between PD and haplotypes of the 
TNFA, IL4, and IL10 cytokine genes in ethnic Russians from East Siberian region of Russia. 
 
2. Material and Methods 
2.1. Study subjects  
The study was approved by the Ethics Committee of the Scientific Research Institute of 
Medical Problems of the North (#12 of 10.12.2013). Signed informed consent was obtained from 
all participants.  
Blood samples from 279 ethnic Russians (West Slavs, Caucasians) were obtained to 
study the haplotypes of single nucleotide polymorphisms (SNPs) of TNFA, IL4, and IL10 genes. 
The sample comprised 77 patients with psoriasis (mean age 32.0±1.92); 99 patients with 
psoriatic arthritis (mean age 48.0±1.79); and 103 healthy control individuals (mean age 
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29.0±0.92) from the city of Krasnoyarsk, Russia. All patients were examined by specialists 
dermatologists in the progressing stage of PS, the degree of severity of the skin process was 
assessed by the PASI (Psoriasis Area and Severity Index). The diagnosis of PsA was assigned 
according to the Classification for Psoriatic Arthritis (CASPAR) criteria (Taylor et al., 2006).  
According to the demographic characteristics, PsA was more often diagnosed in women, and 
psoriasis in men. In the PS group, there were 54 men (70.1%) and 23 women (29.9%), in PsA 
group there were 39 men (39.4%) and 60 women (60.6%). The mean age of psoriatic skin rash in 
PS was 22±1.24 years and in PsA it was 25±1.34 years. Mean age of psoriatic arthritis onset was 
36±1,39 years. Patients with PsA had a higher rate of severe psoriasis with a Psoriasis Area and 
Severity Index (PASI) than those PS patients: 17.9±0.95 vs 13.6±0.83 (p = 0.0007). Psoriasis 
duration in PS was 8±1.15 years and 17±1.38 years in PsA.  
2.2. DNA isolation and genotyping  
DNA was extracted from the blood using DIAtomTM DNA Prep kits (“IzoGen”, Russia). 
Genotyping was carried out using restriction fragment lengths polymorphism (RFLP) approach 
with visualization of the results in agarose gel stained with ethidium bromide. Six 
polymorphisms were studied: TNFA (rs1800629, rs1800630), IL4 (rs2070874, rs2243250) and 
IL10 (rs1800872, rs1800896) (Table 1). The accuracy of the genotyping has been assessed by 
repeated genotyping of a randomly selected 10% of the sample. In all cases, the genotypes were 
concordant upon repeated analysis. 
2.3. Statistical analysis 
 The compliance of the genotype frequencies with Hardy-Weinberg equilibrium was 
tested using Fisher's exact tests. Linkage disequilibrium (LD) between SNPs was calculated 
using package genetics for R programming environment. The association between haplotypes 
and psoriasis were analyzed using the haplo.stats package for R. Haplotype score test was 
applied with 1000 permutations to calculate p-values and logistic regression to obtain odds ratios 
(OR) and respective 95% confidence intervals. Meta-analysis with published data was carried 
out using Mantel-Haenszel approach as implemented in meta package for R.  
 
3. Results and Discussion 
The prevalence of alleles in the studied control sample was in keeping with other world’s 
European populations (according www.ensemble.org data; Table 2). No deviation from HWE 
was observed for TNFA and IL10 in the control group; however, there was the deviation from 
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HWE for IL4 SNPs (p<0.05). The studied SNPs in IL4, IL10, and TNF were in high LD 
according to D’ statistics (Table 3). 
We analyzed associations between PD (PS and PsA) and genotypes and haplotypes of 
cytokine genes TNFA, IL4, IL10 genes. No statistically significant associations were found 
(Supplementary Tables 1A-C). Due to the small number of patients and controls in the current 
study, the results are preliminary. The estimated power to find associations with three haplotypes 
with the given sample size was 41%. Therefore, we set out to carry out meta-analysis of the data 
from previous studies for individual SNPs for TNFA rs1800629, IL4 rs2243250 and IL10 
rs1800896 SNPs.  
For IL4, two study have been published so far to the best of our knowledge: one in a 
Chinese population (Indhumathi et al., 2017) and one in South Indian Tamils (Li et al., 2014). 
Meta-analysis with fixed-effects showed a significant association between PS and IL4 rs2243250 
(OR = 1.27 [1.07-1.50] and OR = 1.23 [1.05-1.46]; Supplementary Figures 1, 2); however, in 
case of PsA, a remarkable heterogeneity between the studies was seen, with the current study 
effects direction being opposite to other two studies. In both cases, random effects model was 
insignificant, though very close to such in case of PS (C vs T allele OR = 1.23 [0.99-1.53]).  
For TNFA, several meta-analyses have been published so far; therefore, we have chosen 
one that provided all necessary tabulated data (Jia et al., 2013) and updated it with the results of 
our study as well as with the results of tree other recent studies (Karam et al., 2014; Cardili et al., 
2015; Popa et al., 2011). For PS, the data were stratified by Caucasian and Asian cohorts, while 
for PsA, only Caucasian cohorts were included because only one small Asian study data were 
provided. Meta-analysis provided evidences for association between PS and TNFA rs1800629 
using both fixed and random effects models: G vs A allele OR = 1.43 [1.26-1.62] and 1.42 [1.22-
1.66], respectively (Supplementary Figure 3). At the same time, no associations between PsA 
and TNFA rs1800629 was observed (Supplementary Figure 4).  
For IL10 rs1800896 we used the studies reported in a meta-analysis by Lee et al. (2012) 
as well as from our study and another recent study (Karam et al., 2014). For PS we used all the 
studies, while for PsA we only used another Caucasian cohort due to the lack of Asian cohorts 
(only one was available). Neither PS nor PsA were found to be associated with the IL10 
polymorphism (Supplementary Figures 5, 6).  
The results of our study provide evidence about positive association between promoter 
polymorphisms of the TNFA gene and PS, but not PsA. It is well known that TNF-α plays a 
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crucial role in autoimmune and infectious diseases as a proinflammatory cytokine; however, the 
mechanism of altered PS and PsA risk owing to SNPs in the TNFA gene promoter region 
remains unknown. A possible explanation is abnormal expression of the TNF-α gene mediated 
by variations in the TNF-α promoter (Zhu et al., 2013).  Expression of the TNF-α has been 
shown to be increased in psoriatic lesions (Baran et al., 2006). TNFA gene is located on 
chromosome 6p21.231 in the polymorphic region of MHC III. SNPs in promoter of the TNFA 
gene at positions -238 and -308 have been associated with psoriasis vulgaris and PsA, though 
due to strong LD at chromosome 6p21, the region known to harbor risk factors for psoriasis 
susceptibility (PSORS1), the interpretation of these findings is difficult (Reich et al., 2007). 
Some studies have shown association of TNFA gene polymorphism and the development of PS 
(Karam et al., 2014), while other studies have reported that G-308A (rs1800629) polymorphism 
decreases the risk of psoriasis (Li et al., 2007) and yet other studies reported no significant 
association between G-308A and PS (Baran et al., 2006; Kim et al., 2003; Tsunemi et al., 2003). 
Similarly, there are conflicting results about association between another polymorphism of 
TNFA gene (rs361525) and PS or PsA (Loft et al., 2018). The curative effect of TNF-α blockers 
in patients with PS and PsA indicates that, to a certain degree, they share common 
immunopathogenesis (Mease, 2004). Therefore, both PS and PsA may have a common risk of 
onset with regard to TNF-α promoter SNPs. The results of a meta-analysis confirmed this 
hypothesis via showing that TNFα -238A/G and TNFα -308A/G polymorphisms are associated 
with susceptibility to both PS and PsA. In Brazilian population, the TNFα −308A/G 
polymorphism was found to be associated with generalized forms of psoriasis (erythrodermic 
and generalized pustular psoriasis) (Cardili et al., 2016). Furthermore, this meta-analysis shows 
that the TNFα -857T/C variant increases the risk of PsA significantly, whereas TNFα -857T/C 
and TNFα -238A/G polymorphisms exhibit risk effects in the pooled analysis of PS and PsA. In 
contrast, the TNFα -308A/G polymorphism has a protective effect for PS and PsA. The -857C/T 
polymorphism was associated with susceptibility to PsA in Romanian population individually (p 
= 0.03, OR 1.65, 95% CI 1.05–2.57) and in haplotypes with the −238G/A and −308G/A SNPs 
(Popa et al., 2011). No significant association between TNFα-308A/G, -1031C/T, or -863A/C 
polymorphism and to PsA alone was revealed (Zhu et al., 2013, Murdaca et al., 2014).   
The results of our meta-analysis provide further evidence about positive association 
between promoter polymorphisms of the IL4 gene and PD. IL-4 plays an important role in the 
pathogenesis of PS and PsA, via suppressing Th1 and Th17 cells and promoting Th2, thus 
preventing the maintenance of IL-17–producing Th17 cells by abrogating the expression and 
production of the Th17 cell-associated cytokine in psoriatic epidermal cells (Ghoreschi et al., 
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2003; Hahn and Ghoreschi, 2017). It was shown that IL-4 treatment improves the course of PS 
(Jain et al., 2009; Hahn and Ghoreschi, 2017, Lotti and Hercogova, 2015). It was supposed that 
the IL4/IL13 gene locus is associated with PS [Nair, 2009]. The gene encoding the IL-4 product 
is located on 5q31.1 chromosome; it exhibits strong association with the development of PS and 
its expression is almost absent in psoriatic skin (Bidwell et al., 1999, Hahn and Ghoreschi, 
2017). The IL4 gene is one of susceptibility genes to PS and PsA, identified in subjects of 
European ethnicity, but not in subjects of Chinese ethnicity (Chandran, 2013). The C-590T 
(rs2243250) polymorphism of the IL4 gene has the greatest functional significance for PS and 
PsA due to its effect on the levels of IL-4 production with the rs2243250*T associated with 
hyperproduction of IL-4 (Chang et al., 2007). The results of the study in South Indian Tamils 
suggest that IL4 (rs2243250) polymorphism is protective against psoriasis and the heterozygous 
C/T genotype demonstrated significant high IL-4 levels in blood (Indhumathi et al., 2017).  In 
contrast, the rs2243250*C allele is associated with the increased risk of PS in another studies 
(Munir et al., 2015; Kim et al., 2007).  
The results of our study of IL10 gene provide no evidence about association between its 
promoter polymorphisms and PS or PsA both in Russians and in other world populations. IL-10 
is a pluripotent anti-inflammatory and immunosuppressive cytokine that plays an important role 
in the regulation of the immune response, including the PS and PsA. Deficiency of IL-10 in PS 
and PsA promotes the launch of autoregulative process of polarization of Th0 cells towards the 
Th2 lymphocytes, which triggers the autoimmune mechanisms of formation of inflammatory 
processes in skin and joints in PS and PsA thereby affecting the phenotype of the disease (Karam 
et al., 2014, Al-Balbeesi et al., 2015). It was found that prolonged use of cytokine therapy of IL-
10 in PS reduces the frequency of exacerbations of the disease, but no similar effect was 
observed with PsA (Lotti and Hercogova, 2015). The IL10 gene is located on 1q31-32 
chromosome (Bidwell et al., 1999, Bowcock and Krueger, 2005). Genetic variants in promotor 
region of IL10 gene are known which affect the level of IL-10 in serum (rs1800890, rs1800896, 
rs1800871, rs1800872) and have the greatest functional role in PS and PsA (Karam et al., 2014; 
Trifunović et al., 2015). The results of the meta-analysis of these polymorphisms showed the 
association of G-1082A polymorphism with the susceptibility to PS in Asians, but not in 
Caucasians, suggesting ethnic-specific effect (Lee et al., 2012). This corroborates with our 
findings in Russians of East Siberia.  
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4. Conclusion 
Genetic polymorphism of the cytokine network affects the level of cytokine concentration 
in the serum, thus mediating the development of psoriatic disease. In the current study, we did 
not establish association between the haplotypes of promoter polymorphisms of TNFA, IL4 and 
IL10 genes in Russians of East Siberia. However, meta-analysis using our new data on the 
Russians and other world populations strengthen the argument about associations between PD 
and the polymorphisms of TNFA and IL4 genes. Thus, the results of the study add value to the 
accumulating data about the impact of cytokine genes polymorphism on the development of 
psoriatic disease.  
 
Conflict of interest 
The authors declare that they have no conflicts of interest, financial or otherwise 
associated with the manuscript. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
9 
 
References 
Al-Balbeesi A.O., Halwani M., Alanazi M., Elrobh M., Shaik J.P., Khan A.A., Parine N.R., 
2015. Novel mutations in IL-10 promoter region -377 (C>T), -150 (C>A) and their 
association with psoriasis in the Saudi population. Asian Pac. J. Cancer Prev. 16(3):1247-
50. https://doi.org/10.7314/apjcp.2015.16.3.1247. 
Baliwag J., Barnes D.H., Johnston A., 2015. Cytokines in psoriasis. Cytokine. 73(2):342-50. 
https://doi.org/10.1016/j.cyto.2014.12.014. 
Baran W., Szepietowski J.C., Mazur G., Baran E., 2006. A - 308 promoter polymorphism of 
tumor necrosis factor alpha gene does not associate with the susceptibility to psoriasis 
vulgaris. No difference either between psoriasis type I and type II patients. Acta. 
Dermatovenerol. Alp. Pannonica. Adriat. 15(3):113-8. 
https://doi.org/10.1016/j.cyto.2007.04.004. 
Bidwell J.L., Wood N.A., Morse H.R., Olomolaiye O.O., Keen L.J., Laundy G.J., 1999. Human 
cytokine gene nucleotide sequence alignments: supplement 1. Eur. J. Immunogenet. 26 
(2-3): 135-223. https://doi.org/10.1046/j.1365-2370.1999.00143.x- i2 
Boehncke W.H., Schön M.P., 2015. Psoriasis. Lancet. 386: 983-94. 
https://doi.org/10.1016/s0140-6736(14)61909-7. 
Bowcock A.M., Krueger J.G., 2005. Getting under the skin: the immunogenetics of psoriasis. 
Nat. Rev. Immunol. 5(9):699-711. https://doi.org/10.1038/nri1689. 
Cardili R.N., Deghaide N.S., Mendes-Junior C.T., Donadi E.A., Souza C.S. HLA-C and TNF 
gene polymorphisms are associated with psoriasis in Brazilian patients. Int J Dermatol. 
2016; 55(1):e16-22. https://doi.org/10.1111/ijd.12894 
Chandran V., 2013. The genetics of psoriasis and psoriatic arthritis. Clin. Rev. Allergy Immunol. 
44 (2): 149–156. https://doi.org/10.4103/0019-5154.62751. 
Chang Y.T., Chou C.T., Yu C.W., Lin M.W., Shiao Y.M., Chen C.C., Huang C.H., Lee D.D., 
Liu H.N., Wang W.J., Tsai S.F., 2007. Cytokine gene polymorphisms in Chinese patients 
with psoriasis. Br. J. Dermatol. 156 (5): 899-905. https://doi.org/10.1111/j.1365-
2133.2007.07820.x. 
Ghoreschi K., Thomas P., Breit S., Dugas M., Mailhammer R., van Eden W., van der Zee R., 
Biedermann T., Prinz J., Mack M., Mrowietz U., Christophers E., Schlöndorff D., Plewig 
G., Sander C.A., Röcken M., 2003. Interleukin-4 therapy of psoriasis induces Th2 
responses and improves human autoimmune disease. Nat. Med. 9(1):40–46. 
https://doi.org/10.1038/nm804 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
10 
 
Hahn M., Ghoreschi K., 2017. The role of IL-4 in psoriasis. Expert. Rev. Clin. Immunol. 
13(3):171-173. https://doi.org/10.1080/1744666x.2017.1279054. 
Indhumathi S., Rajappa M., Chandrashekar L., Ananthanarayanan P.H., Thappa D.M., Negi 
V.S., 2017. T helper-2 cytokine/regulatory T-cell gene polymorphisms and their relation 
with risk of psoriasis in a South Indian Tamil cohort. Hum. Immunol. 78(2):209-215. 
https://doi.org/10.1016/j.humimm.2016.12.006. 
Jain S., Kaur I.R., Das S., Bhattacharya S.N., Singh A., 2009. T helper 1 to T helper 2 shift in 
cytokine expression: an autoregulatory process in superantigen-associated psoriasis 
progression? J. Med. Microbiol. 58 (2): 180-184. https:// doi: 10.1099/jmm.0.003939-0. 
Jia Y., Qin H.J., Zhang J.X., Liu X.L., Li L.J., 2013. Association of the tumour necrosis factor-α 
polymorphisms rs361525 and rs1800629 with susceptibility to psoriasis: a meta-analysis. 
Clin. Exp. Dermatol. 38(8):836-44. https://doi.org/10.1111/ced.12136. 
Karam R.A., Zidan H.E., Khater M.H., 2014. Polymorphisms in the TNF-α and IL-10 gene 
promoters and risk of psoriasis and correlation with disease severity. Cytokine. 66 (2): 
101-115. https://doi.org/10.1016/j.cyto.2014.01.008. 
Kim T.G., Pyo C.W., Hur S.S., Kim Y.K., Hwang H.Y., Youn J.I., Kim T.Y., 2003. 
Polymorphisms of tumor necrosis factor (TNF) alpha and beta genes in Korean patients 
with psoriasis. Arch. Dermatol. Res. 295(1):8-13. https://doi.org/10.1007/s00403-003-
0392-9. 
Kim Y.K., Pyo C.W., Choi H.B., Kim S.Y., Kim T.Y., Kim T.G., 2007. Associations of IL-2 and 
IL-4 gene polymorphisms with psoriasis in the Korean population. J. Dermatol. Sci. 
48(2):133-9. https://doi.org/10.1016/j.jdermsci.2007.06.014. 
Lee Y.H., Choi S.J., Ji J.D., Song G.G., 2012. Associations between interleukin-10 
polymorphisms and susceptibility to psoriasis: a meta-analysis. Inflamm. Res. 61(7):657-
63. https://doi.org/10.1177/0961203311422711. 
Li C., Wang G., Gao Y., Liu L., Gao T., 2007. TNF-alpha gene promoter -238G>A and -
308G>A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis. J. Invest. 
Dermatol. 127(8):1886-92. https:// doi: 10.1038/sj.jid.5700822. 
Li X.L., Wu C.F., Wu G.S., 2014. Genetic variations of cytokines and cytokine receptors in 
psoriasis patients from China. Int. J. Genomics. 2014:870597. 
https://doi.org/10.1155/2014/870597. 
Loft N.D., Skov L., Rasmussen M.K., Gniadecki R., Dam T.N., Brandslund I., Hoffmann H.J., 
Andersen M.R., Dessau R.B., Bergmann A.C., Andersen N.M., Abildtoft M.K., Andersen 
P.S., Hetland M.L., Glintborg B., Bank S., Vogel U., Andersen V., 2018. Genetic 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
11 
 
polymorphisms associated with psoriasis and development of psoriatic arthritis in patients 
with psoriasis. PLoS One. 1;13(2):e0192010. 
https://doi.org/10.1371/journal.pone.0192010. 
Lotti T., Hercogova J., 2015. Successful treatment of psoriasis with low-dose per os interleukins 
4, 10, and 11. Dermatol. Ther. 28(1):1-2.  https://doi.org/10.1111/dth.12174. 
Mease P., 2004. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann. Rheum. Dis. 63: 
755–758. https://doi.org/10.1136/ard.2004.020719. 
Meng S., Lin Z., Wang Y., Wang Z., Li P., Zheng Y., 2018. Psoriasis therapy by Chinese 
medicine and modern agents. Chin. Med. 23;13:16. https://doi.org/10.1186/s13020-018-
0174-0. 
Munir S., ber Rahman S., Rehman S., Saba N., Ahmad W., Nilsson S., Mazhar K., Naluai Å.T., 
2015. Association analysis of GWAS and candidate gene loci in a Pakistani population 
with psoriasis. Mol. Immunol. 64 (1):190-194. 
https://doi.org/10.1016/j.molimm.2014.11.015.  
Murdaca G., Gulli R., Spano F., Lantieri F., Burlando M., Parodi A., Mandich P., Puppo F. TNF 
–α gene polymorphisms: association with disease susceptibility and response to anti-TNF 
–α treatment in psoriatic arthritis. J Invest Dermatol. 2014; 134(10):2503-2509. 
https://doi.org/10.1038/jid.2014.123. 
Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., Gudjonsson J.E., Li Y., 
Tejasvi T., Feng B.J., Ruether A., Schreiber S., Weichenthal M., Gladman D., Rahman 
P., Schrodi S.J., Prahalad S., Guthery S.L., Fischer J., Liao W., Kwok P.Y., Menter A., 
Lathrop G.M., Wise C.A., Begovich A.B., Voorhees J.J., Elder J.T., Krueger G.G., 
Bowcock A.M., Abecasis G.R., 2009. Genome-wide scan reveals association of psoriasis 
with IL-23 and NF-kappaB pathways. Nat. Genet. 41(2):199–204. 
https://doi.org/10.1038/ng.311. 
Nestle F.O., Kaplan D.H., Barker J., 2009. Psoriasis. N. Engl. J. Med. 30; 361(5):496-509. 
https://doi.org/10.1056/nejmra0804595. 
Popa O.M., Bojinca M., Bojinca V., Dutescu M.I., Meirosu M., Caisan R.E., Ciofu C., Bara C., 
Popa L.O. A pilot study of the association of tumor necrosis factor alpha polymorphisms 
with psoriatic arthritis in the Romanian population. Int J Mol Sci. 2011;12(8):5052-9. 
https://doi.org/10.3390/ijms12085052. 
Reich K., Hüffmeier U., König I.R., Lascorz J., Lohmann J., Wendler J., Traupe H., Mössner R., 
Reis A., Burkhardt H.., 2007. TNF polymorphisms in psoriasis: association of psoriatic 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
12 
 
arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk 
allele. Arthritis. Rheum. 56(6):2056-64. https://doi.org/10.1186/ar2244. 
Ritchlin C., 2007. Psoriatic disease--from skin to bone. Nat. Clin. Pract. Rheumatol. 3(12):698-
706. https://doi.org/10.1038/ncprheum0670. 
Ruiz D.G., Azevedo M.N., Santos O.L., 2012. Psoriatic arthritis: a clinical entity distinct from 
psoriasis? Rev. Bras. Reumatol. 52: 630–638. https://doi.org/10.6061/clinics/2012(03)08 
Sakkas L.I., Bogdanos D.P., 2017. Are psoriasis and psoriatic arthritis the same disease? The IL-
23/IL-17 axis data. Autoimmun. Rev. 16(1):10-15. 
https://doi.org/10.1016/j.autrev.2016.09.015. 
Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H. Classification 
criteria for psoriatic arthritis: development of new criteria from a large international 
study. Arthritis Rheum 2006; 54: 2665–2673. https://doi.org/10.1002/art.21972. 
Trifunović J., Miller L., Debeljak Ž., Horvat V., 2015. Pathologic patterns of interleukin 10 
expression--a review. Biochem. Med. (Zagreb) 25(1):36-48. 
https://doi.org/10.11613/bm.2015.004 
Tsunemi Y., Nishibu A., Saeki H., Oyama N., Nakamura K., Kishimoto M., Mitsui H., Tada Y., 
Torii H., Komine M., Asahina A., Kaneko F., Tamaki K., 2003. Lack of association 
between the promoter polymorphisms at positions -308 and -238 of the tumor necrosis 
factor alpha gene and psoriasis vulgaris in Japanese patients. Dermatology. 207(4):371-4. 
https://doi.org/10.1159/000074117. 
Zhu J., Qu H., Chen X., Wang H., Li J., 2013. Single nucleotide polymorphisms in the tumor 
necrosis factor-alpha gene promoter region alter the risk of psoriasis vulgaris and 
psoriatic arthritis: a meta-analysis. PLoS One. 23;8(5):e64376. https:// doi: 
10.1371/journal.pone.0064376 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
13 
 
 
Table 1 – Oligonucleotide primers, annealing temperature, restriction endonucleases and products of endonuclease 
hydrolysis for the studied polymorphisms of the cytokine genes  
 
Gene 
Polymorphism 
(SNP) 
Sequence of primers 
Annealing 
temperature, 
°С 
Restriction 
enzyme 
Products of 
restriction 
enzyme 
hydrolisis (bp), 
allelic variants 
TNFA 
G-308A 
rs1800629 
5’-aggcaataggttttgagggccat-3’ 
5’-acactccccatcctcccggct-3’ 
58 Bsp19 I 
G: 97, 20 
A: 117 
TNFA 
C-863A 
rs1800630 
5’-ggctctgaggaatgggttac-3’ 
5’-ctacatggccctgtcttcgttacg-3’ 
60 BstBA I 
C: 125 
A: 102, 23 
IL4 
C-33T 
rs2070874 
5'- caagttactgacaatctggtgt-3' 
5'- cggcacatgctagcaggaa-3' 
60 
 
BstMA I 
 
C: 178, 45 
T: 140,45, 38 
IL4 
C-590T 
rs2243250 
5’-cacctaaacttgggagaacatggt-3’ 
5’-gttgtaatgcagtcctcctg-3’ 
60 Bme 18I 
C: 192, 60 
T: 252 
IL10 
C-592A 
rs1800872 
5’-atccaagacaacactactaa-3’ 
5’-taaatatcctcaaagttcc-3’ 
54 Rsa I 
C: 306, 232, 42 
A: 240, 232, 66, 
42 
IL10 
G-1082A 
rs1800896 
5’-aaggcaacactactaaggcttcctt-3’ 
5’-taaatatcctcaaagttcc-3’ 
53 BstEN I 
G: 310, 280 
A: 310, 252, 28 
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Table 2 – Frequencies of allelic polymorphisms of cytokine genes (%) 
 
Genotype 
PS 
(n=77) 
PsA 
(n=99) 
Control group 
(n=103) 
TNFA (rs1800629) 
GG 87.0 80.8 85.4 
GA 13.0 18.2 11.7 
AA 0 1.0 2.9 
TNFA (rs1800630) 
CC 84.4 77.8 76.7 
CA 15.6 19.2 23.3 
AA 0 3.0 0 
IL4(rs2070874) 
CC 62.3 63.6 66.0 
CT 33.8 27.3 25.3 
TT 3.9 9.1 8.7 
IL4 (rs2243250) 
CC 55.8 67.7 67.0 
CT 39.0 24.2 24.3 
TT 5.2 8.1 8.7 
IL10 (rs1800872) 
CC 58.4 57.6 57.3 
CA 36.4 39.4 34.0 
AA 5.2 3.0 8.7 
IL10 (rs1800896) 
AA 29.8 26.3 28.2 
GA 48.1 51.5 57.3 
GG 22.1 22.2 14.5 
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Table 3 – Linkage disequilibrium between the studies SNPs  
 
Gene SNP1 SNP2 Lewontin’s D' r2 χ2 p-value 
IL4 rs2070874 rs2243250 0.893 0.797 444.8375 <0.0001 
IL10 rs1800872 rs1800896 0.950 0.238 132.7267 <0.0001 
TNF rs1800629 rs1800630 0.994 0.011 6.218431 0.0126 
 
Note: According to D’ there is strong LD between all the studies SNP (also confirmed by significant p-
values), but r2 gives low values. Such the situation with r2 may happen when minor allele frequencies 
(MAF) are rather low or when there is a remarkable discrepancy in MAFs for the SNPs (the case in our 
study). 
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Psoriasis (PS) and psoriatic arthritis (PsA) are immune-mediated diseases with different heredity 
that might in part be explained by different genetic factors.  
We carried out an analysis of association between haplotypes of cytokine genes (TNFA, IL4 and 
IL10) and PD in Russians from East Siberian region of Russia. 
The haplotypes were not found to be associated with either PS or PsA.  
Meta-analyses with published data suggested associations between PS and IL4 rs2243250 and 
TNFA rs1800629 polymorphisms, while PsA was found to be associated with IL4 rs2243250 
only. 
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